Back to Search
Start Over
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial
- Source :
- The Lancet HIV; May 2022, Vol. 9 Issue: 5 pe332-e340, 9p
- Publication Year :
- 2022
-
Abstract
- Safe and potent antiretroviral medications in child-friendly formulations are needed to treat young children living with HIV-1. We aimed to select dosing for a dispersible tablet formulation of dolutegravir that achieved pharmacokinetic exposures similar to those in adults, and was safe and well tolerated in young children.
Details
- Language :
- English
- ISSN :
- 24054704 and 23523018
- Volume :
- 9
- Issue :
- 5
- Database :
- Supplemental Index
- Journal :
- The Lancet HIV
- Publication Type :
- Periodical
- Accession number :
- ejs59525239
- Full Text :
- https://doi.org/10.1016/S2352-3018(22)00044-3